Evidence map›Paper›PMID 34822175›Full record

ArticleAmerican journal of hematology2022

Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients.

Patrick W Mellors, Taxiarchis Kourelis, Ronald S Go, Eli Muchtar, Morie A Gertz, Shaji K Kumar, Francis K Buadi, Prashant Kapoor, Martha Q Lacy, David Dingli and 12 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. POEMS syndrome: diagnosis, treatments, and outcomes.Hematology. American Society of Hematology. Education Program · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Patrick W MellorsDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-3127-2124
Taxiarchis KourelisDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-8573-9434
Ronald S GoDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-2210-2174
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-3853-5196
Shaji K KumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-5392-9284
Francis K BuadiDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Martha Q LacyDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
David DingliDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Yi HwaDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-8163-2979
Amie FonderDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Miriam HobbsDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Suzanne HaymanDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-0240-0326
Nelson R LeungDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5651-1411
Yi LinDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Wilson GonsalvesDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6890-969X
Mustaqeem SiddiquiDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Robert A KyleDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5862-1833
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-8780-9512
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
Mayo Clinic StARR ProgramR38HL150086 · NHLBI · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC, KARL A. NATH · 2020 to 2026
$2.5M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA186781NHLBI NIH HHS R38 HL150086
6 · The paper itself

Abstract

Thromboses are prevalent in POEMS syndrome, but few risk factors for POEMS-associated thrombosis have been identified. The objective of this study is to identify novel risk factors for POEMS-associated thrombosis. In this retrospective cohort of 230 POEMS patients, 27% developed thrombosis. Arterial events were slightly more common than venous. Stroke accounted for 26% of all thromboses and 53% of arterial events. There were differences in baseline features between the thrombosis group and the no thrombosis group, and these were driven by patients with arterial thrombosis. Risk factors for arterial thrombosis included thrombocytosis, elevated hemoglobin/hematocrit, extravascular volume overload, and splenomegaly. Hyperprolactinemia appeared to be a risk factor for venous thrombosis. The risk of thrombosis was most striking among men with elevated hemoglobin (32% vs. 5%, p < .001) and hematocrit (42% vs. 5%, p < .001) compared to men without. Most thromboses occurred prior to POEMS directed therapy, and most that occurred during therapy happened within 3 months of diagnosis. Twenty-one percent of patients with thrombosis had recurrence. In recognition of high overall rates of thrombosis in this population, all patients with POEMS syndrome should receive prophylactic antiplatelet therapy, and clinicians should consider anticoagulation in patients with risk factors for POEMS-associated thrombosis.

Indexed as

AdultFemaleHumansMaleMiddle AgedPOEMS SyndromeRetrospective StudiesRisk FactorsThrombosis

Identifiers

PMID34822175
PMCPMC8738145
OpenAlexW3216659934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.